GreenMJ. The innovator will prevail in glucose monitoring. Med Device Technol. 2006; 17 (4): 32–3.
2.
Cronquist Christensen RemlerDM. Information and communications technology in chronic disease care: what are the implications for payment?. Med Care Res Rev. 2007; 64 (2): 123–47.
3.
PalmerAJDinneenSGavinJR3rdGrayAHermanWHKarterAJ. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. Curr Med Res Opin. 2006; 22 (5): 861–72.
4.
WaughNScotlandGMcNameePGillettMBrennanGoyder EWilliamsRJohnA. Screening for type 2 diabetes: literature review and economic modeling. Health Technol Assess. 2007(17); 11: 1–125.
5.
StrakaRJMamdaniMDamenJKuntzeCELiuLZBottemanMFKorenMJ. Economic impacts attributable to the early clinical benefit of atorvastatin therapy—a US managed care perspective. Curr Med Res Opin. 2007; 23 (7): 1517–29.
6.
LindgrenPLindströmJTuomilehtoJUusitupaMPeltonenMJönssonBde FaireUHelléniusML; DPS Study Group. Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care. 2007; 23 (2): 177–83.
7.
SchmittdielJVijanSFiremanBLafataJEOestreicherNSelbyJV. Predicted quality-adjusted life years as a composite measure of the clinical value of diabetes risk factor control. Med Care. 2007; 45 (4): 315–21.
8.
MillettCGrayJSaxenaSNetuveliGMajeedA. Impact of a pay-for-performance incentive on support for smoking cessation and on smoking prevalence among people with diabetes. CMAJ. 2007; 176 (12): 1705–10.
